Collagen Solutions has announced that the final patient in the company’s eight-year follow-up study for its ChondroMimetic product has been assessed. In the near-term the data from all 15 patients will now be analysed. Assuming a successful outcome, Collagen Solutions will apply for CE mark which would allow the product to be marketed in Europe. The company is targeting commercialisation by mid-2018. We maintain our Buy recommendation.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
ChondroMimetic: Last Patient
- Published:
21 Sep 2017 -
Author:
Chris Donnellan -
Pages:
6
Collagen Solutions has announced that the final patient in the company’s eight-year follow-up study for its ChondroMimetic product has been assessed. In the near-term the data from all 15 patients will now be analysed. Assuming a successful outcome, Collagen Solutions will apply for CE mark which would allow the product to be marketed in Europe. The company is targeting commercialisation by mid-2018. We maintain our Buy recommendation.